- Home
- PROK vs SGMT Comparison
PROK vs SGMT Comparison
Compare PROK & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- SGMT
- Stock Information
- Founded
- PROK 2015
- SGMT 2006
- Country
- PROK United States
- SGMT United States
- Employees
- PROK N/A
- SGMT N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- SGMT
- Sector
- PROK Health Care
- SGMT
- Exchange
- PROK Nasdaq
- SGMT Nasdaq
- Market Cap
- PROK 186.8M
- SGMT 165.4M
- IPO Year
- PROK N/A
- SGMT 2023
- Fundamental
- Price
- PROK $1.05
- SGMT $3.68
- Analyst Decision
- PROK Buy
- SGMT Strong Buy
- Analyst Count
- PROK 5
- SGMT 7
- Target Price
- PROK $4.50
- SGMT $25.71
- AVG Volume (30 Days)
- PROK 546.9K
- SGMT 600.4K
- Earning Date
- PROK 03-21-2025
- SGMT 03-24-2025
- Dividend Yield
- PROK N/A
- SGMT N/A
- EPS Growth
- PROK N/A
- SGMT N/A
- EPS
- PROK N/A
- SGMT N/A
- Revenue
- PROK N/A
- SGMT N/A
- Revenue This Year
- PROK N/A
- SGMT N/A
- Revenue Next Year
- PROK N/A
- SGMT N/A
- P/E Ratio
- PROK N/A
- SGMT N/A
- Revenue Growth
- PROK N/A
- SGMT N/A
- 52 Week Low
- PROK $0.98
- SGMT $2.39
- 52 Week High
- PROK $4.44
- SGMT $7.38
- Technical
- Relative Strength Index (RSI)
- PROK 23.63
- SGMT 41.40
- Support Level
- PROK $0.98
- SGMT $3.25
- Resistance Level
- PROK $1.32
- SGMT $3.84
- Average True Range (ATR)
- PROK 0.11
- SGMT 0.30
- MACD
- PROK -0.04
- SGMT -0.01
- Stochastic Oscillator
- PROK 10.61
- SGMT 35.51
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).